INSP delivered exceptional revenue growth of 293% alongside strong profitability expansion, while significantly expanding its patient treatment base from 90,000 to 125,000 patients.
The massive revenue acceleration combined with sustained high profitability demonstrates strong market adoption of Inspire's sleep apnea therapy. However, the company reduced its U.S. sales territories from 335 to 295 despite this growth, which could signal either operational efficiency improvements or market saturation concerns that warrant monitoring.
INSP showed remarkable financial performance with revenue surging 293% to $82M while net income grew 172% to $145.4M, maintaining exceptional profitability margins. The company invested heavily in inventory (up 81%) to support growth while increasing share buybacks to $175M, though cash declined 30% to $105M. The overall picture signals a rapidly scaling business with strong cash generation, though the cash decline and inventory buildup suggest management is investing aggressively for continued expansion.
Strong top-line growth of 293.3% — accelerating demand or successful expansion into new markets.
Net income grew 171.8% — bottom-line growth signals improving overall business health.
Share repurchases increased 133.4% — management returning capital, signals confidence in intrinsic value.
Inventory surged 81.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Cash declined 30.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Receivables grew 28.6% — monitor days sales outstanding for collection efficiency.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Equity base grew 13.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →